Deutsch
 
Benutzerhandbuch Datenschutzhinweis Impressum Kontakt
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells

Garcia-Marquez, M. A., Shimabukuro-Vornhagen, A., Theurich, S., Kochanek, M., Weber, T., Wennhold, K., et al. (2014). A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells. Cytotherapy, 16(11), 1537-44. doi:10.1016/j.jcyt.2014.05.011.

Item is

Basisdaten

einblenden: ausblenden:
Datensatz-Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-58E2-F Versions-Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-58E3-D
Genre: Zeitschriftenartikel

Externe Referenzen

einblenden:
ausblenden:
externe Referenz:
http://www.ncbi.nlm.nih.gov/pubmed/25287602 (beliebiger Volltext)
Beschreibung:
-

Urheber

einblenden:
ausblenden:
 Urheber:
Garcia-Marquez, M. A.1, Autor
Shimabukuro-Vornhagen, A.1, Autor
Theurich, S.1, Autor
Kochanek, M.1, Autor
Weber, T.1, Autor
Wennhold, K.1, Autor
Dauben, A.1, Autor
Dzionek, A.1, Autor
Reinhard, C.1, Autor
von Bergwelt-Baildon, M.1, Autor
Affiliations:
1Max Planck Institute for Biology of Ageing, Max Planck Society, Joseph-Stelzmann-Str. 9b, D-50931 Cologne, DE, ou_1942284              

Inhalt

einblenden:
ausblenden:
Schlagwörter: Apc B cells Cd40l antigen presentation immunotherapy proliferation
 Zusammenfassung: BACKGROUND AIMS: CD40-activated B cells have long been studied as potent antigen-presenting cells that can potentially be used for cancer immunotherapy. Nevertheless, their use in human clinical trials has been limited by the lack of a Good Manufacturing Practice-grade soluble human CD40 ligand that is able to induce activation and proliferation of primary B cells. We describe an in vitro method to effectively generate and expand B cells through the use of a multimerized form of human recombinant CD40 ligand (rCD40L). METHODS: Human B cells were isolated from healthy donors and cultivated with either rCD40L or on a monolayer of murine NIH3T3 cells stably expressing human CD40L (NIH3T3/tCD40L) as a widely used standard method. Morphology, expansion rate, immune phenotype and antigen presentation function were assessed. RESULTS: B cells efficiently proliferated in response to rCD40L over 14 days of culture in comparable amounts to NIH3T3/tCD40L. B-cell division in response to CD40L was also confirmed by carboxyfluorescein succinimidyl ester dilution. Moreover, rCD40L induced on B cells upregulation of co-stimulatory molecules essential for antigen presentation. Additionally, proliferation of T cells from allogeneic healthy volunteers confirmed the immunostimulatory capacities of CD40-activated B cells. CONCLUSIONS: We demonstrated that B cells with potent antigen presentation capacity can be generated and expanded by use of a non-xenogeneic form of CD40L that could be implemented in future human clinical settings.

Details

einblenden:
ausblenden:
Sprache(n):
 Datum: 2014
 Publikationsstatus: Im Druck publiziert
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: Anderer: 25287602
DOI: 10.1016/j.jcyt.2014.05.011
ISSN: 1477-2566 (Electronic)1465-3249 (Linking)
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Cytotherapy
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: -
Seiten: - Band / Heft: 16 (11) Artikelnummer: - Start- / Endseite: 1537 - 44 Identifikator: -